High Serum YKL-40 Level in a Cohort of Octogenarians is Associated with Increased Risk of All-cause Mortality

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2007 Dec 12

PMID 18070151

Citations 25

Authors

J S Johansen

A N Pedersen

M Schroll

T Jorgensen

B K Pedersen

H Bruunsgaard

Affiliations

Soon will be listed here.

Abstract

YKL-40 is secreted by macrophages, neutrophils, chondrocytes, endothelial-, vascular smooth muscle- and cancer cells. Interleukin (IL)-6 stimulates YKL-40 production in human in vivo studies. High serum YKL-40 is associated with poor prognosis in patients with inflammatory diseases and cancer. We studied whether serum YKL-40 was associated with systemic low-level inflammation, an immune risk phenotype, and mortality in relatively healthy 80-year old humans. Serum YKL-40, IL-6 and tumour necrosis factor (TNF)-alpha were measured by enzyme-linked immunosorbent assays (ELISAs) in octogenarians (n = 151) and serum YKL-40 in 18-30-year-olds (n = 89). Fifty-one of the octogenarians died during the 6-year follow-up. Serum YKL-40 in octogenarians was higher compared to the level in young people (median 116 versus 31 microg/l, P < 0.0005). Serum YKL-40 correlated with serum IL-6 in elderly women (Spearman's rho = 0.30, P = 0.009) and men (rho = 0.25, P = 0.003), but only with serum TNF-alpha (rho = 0.23, P = 0.05) and C-reactive protein (CRP) (rho = 0.57, P < 0.0005) among the elderly women. In addition, high serum level of YKL-40 was associated with a low CD4 : CD8 cell ratio. Univariate analysis of serum YKL-40 (logarithmically transformed and divided by tertiles) showed significant association with all-cause mortality [tertile 3: hazard ratio (HR) = 2.38, 95% confidence interval (CI): 1.19-4.78, P = 0.02]. The effect persisted after adjusting for potential confounders (sex, smoking, body mass index, chronic disease and anti-inflammatory medicine). These results suggest that serum YKL-40 is a prognostic and sensitive biomarker of all-cause mortality in octogenarians.

Citing Articles

Development of a predictive algorithm for patient survival after traumatic injury using a five analyte blood panel.

Fathi P, Karkanitsa M, Rupert A, Lin A, Darrah J, Thomas F medRxiv. 2024; .

PMID: 38903094 PMC: 11188118. DOI: 10.1101/2024.04.22.24306188.

van Sleen Y, Shetty S, van der Heiden M, Venema M, Gutierrez-Melo N, Toonen E Immun Ageing. 2023; 20(1):68.

PMID: 38012652 PMC: 10680197. DOI: 10.1186/s12979-023-00391-3.

Proteome-Wide Analysis Using SOMAscan Identifies and Validates Chitinase-3-Like Protein 1 as a Risk and Disease Marker of Delirium Among Older Adults Undergoing Major Elective Surgery.

Vasunilashorn S, Dillon S, Chan N, Fong T, Joseph M, Tripp B J Gerontol A Biol Sci Med Sci. 2022; 77(3):484-493.

PMID: 35239952 PMC: 8893174. DOI: 10.1093/gerona/glaa326.

Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19.

Kamle S, Ma B, He C, Akosman B, Zhou Y, Lee C JCI Insight. 2021; 6(21).

PMID: 34747367 PMC: 8663553. DOI: 10.1172/jci.insight.148749.

Identification of serum prognostic biomarkers of severe COVID-19 using a quantitative proteomic approach.

Kimura Y, Nakai Y, Shin J, Hara M, Takeda Y, Kubo S Sci Rep. 2021; 11(1):20638.

PMID: 34667241 PMC: 8526747. DOI: 10.1038/s41598-021-98253-9.

References

Belge K, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B . The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. 2002; 168(7):3536-42. DOI: 10.4049/jimmunol.168.7.3536. View

Gabay C, Kushner I . Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340(6):448-54. DOI: 10.1056/NEJM199902113400607. View

Kushner I, Rzewnicki D, Samols D . What does minor elevation of C-reactive protein signify?. Am J Med. 2006; 119(2):166.e17-28. DOI: 10.1016/j.amjmed.2005.06.057. View

Millis A, Hoyle M, Reich E, Mann D . Isolation and characterization of a Mr = 38,000 protein from differentiating smooth muscle cells. J Biol Chem. 1985; 260(6):3754-61. View

Bruunsgaard H, Ladelund S, Pedersen A, Schroll M, Jorgensen T, Pedersen B . Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol. 2003; 132(1):24-31. PMC: 1808682. DOI: 10.1046/j.1365-2249.2003.02137.x. View

Kronborg G, Ostergaard C, Weis N, Nielsen H, Obel N, Pedersen S . Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease. Scand J Infect Dis. 2002; 34(5):323-6. DOI: 10.1080/00365540110080233. View

Malinda K, Ponce L, Kleinman H, Shackelton L, Millis A . Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res. 1999; 250(1):168-73. DOI: 10.1006/excr.1999.4511. View

Johansen J, Baslund B, Garbarsch C, Hansen M, Stoltenberg M, Lorenzen I . YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum. 2000; 42(12):2624-30. DOI: 10.1002/1529-0131(199912)42:12<2624::AID-ANR17>3.0.CO;2-K. View

Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E . Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000; 908:244-54. DOI: 10.1111/j.1749-6632.2000.tb06651.x. View

10.

Maggio M, Guralnik J, Longo D, Ferrucci L . Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci. 2006; 61(6):575-84. PMC: 2645627. DOI: 10.1093/gerona/61.6.575. View

11.

Johansen J, Krabbe K, Moller K, Pedersen B . Circulating YKL-40 levels during human endotoxaemia. Clin Exp Immunol. 2005; 140(2):343-8. PMC: 1809363. DOI: 10.1111/j.1365-2249.2005.02763.x. View

12.

DelaRosa O, Pawelec G, Peralbo E, Wikby A, Mariani E, Mocchegiani E . Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. Biogerontology. 2006; 7(5-6):471-81. DOI: 10.1007/s10522-006-9062-6. View

13.

Johansen J, Milman N, Hansen M, Garbarsch C, Price P, Graudal N . Increased serum YKL-40 in patients with pulmonary sarcoidosis--a potential marker of disease activity?. Respir Med. 2005; 99(4):396-402. DOI: 10.1016/j.rmed.2004.09.016. View

14.

Rehli M, Krause S, Andreesen R . Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997; 43(2):221-5. DOI: 10.1006/geno.1997.4778. View

15.

Bruunsgaard H, Andersen-Ranberg K, Hjelmborg J, Pedersen B, Jeune B . Elevated levels of tumor necrosis factor alpha and mortality in centenarians. Am J Med. 2003; 115(4):278-83. DOI: 10.1016/s0002-9343(03)00329-2. View

16.

Junker N, Johansen J, Hansen L, Lund E, Kristjansen P . Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci. 2005; 96(3):183-90. PMC: 11158589. DOI: 10.1111/j.1349-7006.2005.00026.x. View

17.

Nishikawa K, Millis A . gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res. 2003; 287(1):79-87. DOI: 10.1016/s0014-4827(03)00069-7. View

18.

Papanicolaou D, Wilder R, Manolagas S, Chrousos G . The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998; 128(2):127-37. DOI: 10.7326/0003-4819-128-2-199801150-00009. View

19.

Boot R, van Achterberg T, van Aken B, Renkema G, Jacobs M, Aerts J . Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol. 1999; 19(3):687-94. DOI: 10.1161/01.atv.19.3.687. View

20.

Krabbe K, Pedersen M, Bruunsgaard H . Inflammatory mediators in the elderly. Exp Gerontol. 2004; 39(5):687-99. DOI: 10.1016/j.exger.2004.01.009. View